• Machine Learning Reveals Three Senolytic Candidates

  2026-09-23

  The study used machine learning trained on published data to prioritize compounds for senolytic testing, then validated ginkgetin, periplocin, and oleandrin in human cell models of senescence. Its main contribution is a data-efficient route from scattered literature results to experimentally testable candidates, while highlighting the need to confirm selectivity across cell types and senescence models.

• miR-18a–ALOXE3 Signaling in Glioblastoma

  2026-09-23

  The reference study identifies a miR-18a–ALOXE3 axis that connects ferroptosis resistance with enhanced glioblastoma migration. Its combination of human tumor analysis, genetic perturbation, lipid mediator studies, and orthotopic modeling provides a useful framework for separating tumor-cell survival from motility mechanisms.

• NMN, SIRT3, and Diabetic Myocardial Fibrosis

  2026-09-22

  A 2026 mouse study links NMN treatment with reduced diabetic myocardial fibrosis through a proposed SIRT3–GSK3β–Smad3 mechanism. The work is notable for connecting NAD+-related metabolic regulation with protein acetylation and cardiac remodeling, although its evidence remains pharmacological and preclinical.

• Palonosetron: From Receptor Kinetics to Translation

  2026-09-22

  Palonosetron hydrochloride illustrates how receptor residence, subtype selectivity, and exposure duration can reshape translational antiemetic strategy. This thought-leadership guide connects 5-HT3 pharmacology with assay design, renal transporter considerations, and clinical prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.

• Tetrahydromagnolol: A GPCR Assay Design Framework

  2026-09-21

  Tetrahydromagnolol is a peripheral CB2 receptor agonist with a distinctive CB2–GPR55 pharmacology. This guide translates its reported potency values and a new GPCR–cytoskeleton metastasis study into a mechanism-resolved experimental strategy.

• Etomoxir: CPT-1 Inhibition in Metabolic Research

  2026-09-21

  Etomoxir is a cell-permeable, irreversible CPT-1 inhibitor used to test fatty acid oxidation dependence in cellular and immunometabolic systems. R-(+)-Etomoxir research requires attention to stereochemical identity, concentration-dependent DGAT inhibition, and the limits of translating EAE findings to human disease.

• SW033291: A Translational Map for Regeneration

  2026-09-20

  SW033291 is a potent 15-PGDH inhibitor that links prostaglandin E2 elevation with hematopoiesis stimulation and tissue regeneration research. This thought-leadership guide translates biochemical potency, marrow-cell assays, and emerging muscle-repair evidence into a disciplined strategy for target validation and translational study design.

• SB 431542: A Practical ALK5 Inhibitor Workflow

  2026-09-19

  SB 431542 enables focused interrogation of ALK5-dependent TGF-β signaling, from Smad2 phosphorylation assays to intestinal epithelial and glioma models. This guide translates reference-study findings into executable workflows, controls, and troubleshooting strategies without treating pathway inhibition as proof of therapeutic benefit.

• Pollen Interference in EEM Hazard Classification

  2026-09-18

  A 2024 Molecules study shows that pollen can distort excitation–emission matrix fluorescence classification of hazardous bioaerosol components. Combining spectral preprocessing, fast Fourier transform features, and random-forest modeling improved discrimination across 31 sample types and offers a practical strategy for reducing pollen-associated misclassification.

• X-Gal Workflow for Blue-White Screening

  2026-09-18

  Build a more reliable blue-white colony screening workflow with practical guidance on substrate preparation, plate conditions, clone selection, and confirmation. The article also shows how X-Gal can support plasmid construction for olfactory receptor and iRhom2 studies without being mistaken for a direct pathway assay.

• Zolmitriptan Workflows for 5-HT1B Research

  2026-09-17

  Build reproducible receptor-signaling, vascular, and neuropeptide-release assays with Zolmitriptan, a selective 5-HT1B receptor agonist for migraine and cluster headache research. This workflow emphasizes solvent control, subtype-resolved experiments, orthogonal validation, and time-resolved assay design without overstating evidence from unrelated lysosomal studies.

• LINC01977, Super-Enhancers, and SMAD3 in Early LUAD

  2026-09-17

  Zhang et al. identify LINC01977 as a super-enhancer-hijacked long noncoding RNA that reinforces canonical TGF-β/SMAD3 signaling in early-stage lung adenocarcinoma. The study connects tumor-associated macrophage activity, enhancer regulation, SMAD3 nuclear function, and ZEB1-mediated malignancy, providing a mechanistic framework for studying epigenetic drivers of relapse and invasion.

• Sex-Biased Gene Expression in Neural hESCs

  2026-09-16

  Pottmeier and colleagues used multiple male- and female-derived human embryonic stem cell lines to identify genetic sex biases during neural differentiation without treating hormonal exposure as the primary driver. Their transcriptomic analysis highlights neurodevelopmental candidate genes, Y-linked regulators, and a stronger contribution from the male transcriptome, providing a framework for studying sex-dependent developmental trajectories.

• Bay 11-7821 in NF-κB Inflammation Workflows

  2026-09-16

  Bay 11-7821 (BAY 11-7082) gives researchers a practical way to test whether IKK–NF-κB activity links innate immune stimulation to cytokine output, cell survival, or tumor-cell growth. This workflow-focused guide covers monocyte inflammation assays, cancer models, controls, dosing logic, and troubleshooting.

• 25-Hydroxycholesterol Reprograms Tumor Macrophages

  2026-09-15

  The 2024 Immunity study identifies CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that links lysosomal sterol handling to AMPKα–STAT6 signaling and ARG1 production in tumor-associated macrophages. Its findings provide a mechanistic explanation for macrophage-mediated immune suppression and show why CH25H targeting can improve T-cell surveillance and anti-PD-1 responses.

8582 records 1/573 page Next 12345 下5页 Last page